Table 3.

Risk of GC-related and GC-unrelated organ damage development during 2-year follow-up across different patterns of GC tapering in 127 patients with newly diagnosed SLE starting concomitant hydroxychloroquine or immunosuppressants

	GC-related damage				GC-unrelated damage
	Crude OR (95% CI)	P	Adj OR* (95% CI)	P	Crude OR (95% CI)	P	Adj OR* (95% CI)	P
Tapering PDN <5 mg/day	Ref.		Ref.		Ref.		Ref.
Fail to taper PDN <5 mg/day	0.86 (0.21 to 3.22)	0.824	0.98 (0.20 to 4.45)	0.975	0.69 (0.25 to 1.81)	0.457	1.02 (0.32 to 3.24)	0.967
Never tapered PDN <5 mg/day	4.54 (1.47 to 15.10)	0.010	5.90 (1.53 to 27.0)	0.014	1.89 (0.71 to 5.03)	0.197	2.28 (0.70 to 7.57)	0.168

*Adjusted for age, gender, ECLAM score, baseline SDI and PDN daily dose.

ECLAM, European Consensus Lupus Activity Measurement; GC, glucocorticoid; PDN, prednisone; SLE, systemic lupus erythematosus.